CNDO Stock News 1.60 05/13/2014 02:56:12 Coronado Biosciences

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 3:56 AM

Coronado Biosciences (CNDO) 1.60 $CNDO

Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2014
GlobeNewswire - Mon May 12, 7:11AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced today its financial results for the first quarter ended March 31, 2014.

Coronado Biosciences Announces February Inducement Award
GlobeNewswire - Fri May 09, 3:05PM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) inadvertently failed to file a press release as required by NASDAQ listing rule 5635c4 when it reported certain transactions on Form 8-K/A filed with the Securities and Exchange Commission on February 26, 2014. This press release is being filed to rectify this lapse.

Coronado Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 9:13AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO), announced today that Dr. Lindsay A. Rosenwald, Coronado's Chairman, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, at 2:20 PM PT. The conference will be held at the Encore at the Wynne Las Vegas on May 13-15, 2014. A webcast of the presentation will be available at www.coronadobiosciences.com on the Events & Webcasts page.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic

Pipeline Progress at Coronado Biosciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:20PM CDT
Coronado Biosciences commenced a study evaluating TSO for the treatment of pediatric patients with autism spectrum disorder.

Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Pediatric Patients With Autism Spectrum Disorder
GlobeNewswire - Thu Apr 10, 3:35PM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that an Investigator-Initiated Study evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) has initiated. The study is being conducted by the Hadassah-Hebrew University Medical Center in Jerusalem, Israel. Dr. Itai Berger, Director of its Neuro-Cognitive Center, is the Principal Investigator of the trial.

Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Fri Mar 14, 6:03AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced its financial results for the fourth quarter and year ended December 31, 2013.

Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:24AM CST
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)?

Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.

5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.

Qiagen to Simplify Next-Generation Sequencing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:00PM CST
Qiagen recently divulged its plans to launch innovative products.

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Thursday

Coronado Shares Continue to Soar on Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 4:00PM CST
The USPTO has granted a second key patent for Coronado's CNDO-109.

Coronado Biosciences Granted a Second Key Patent for CNDO-109, an Activator of Natural Killer Cells
GlobeNewswire - Thu Feb 06, 7:00AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as the licensing and acquisition of, and investment in, development stage compounds, biologics and companies, today announced the U.S. Patent and Trademark Office (USPTO) has granted a second key patent for CNDO-109 directed to the activated Natural Killer (NK) cell compositions employed in its NK cell therapy program, and has further issued a Notice of Allowance in an additional pending application directed to pharmaceutical compositions comprising these activated NK cells. The activated NK cells are prepared by a patented process licensed by Coronado from UCL Business PLC, which is already the subject of a previously-granted U.S. patent. Similar patent protection has been obtained in Australia and India and applications are still pending in Europe, Japan and Canada.

Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.

Why XOMA Corporation (XOMA) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:40AM CST
XOMA Corporation has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy

Coronado Biosciences (CNDO) Jumps: Stock Up 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:39AM CST
Coronado Biosciences, Inc. was a big mover last session, as its shares rose over 6% on the day.

Why Acceleron (XLRN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 7:30AM CST
Acceleron has seen its Zacks Rank move up from Neutral to Buy over the past four weeks

5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Salveo Home Care Faces Class Action Over Labor Violations

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...